Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2023). On theSindex it has a DataRank of 1.0. It has been cited 45 times, with 45 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
- ClinicalTrials.govNCT03800602
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
›Methodology & internals
FAIR Checklist
Context only (not used in score)- Has DOI
- Open Access
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
DataRank Breakdown
Base Score Contribution
0.574
From this paper's citation signal
Citation Network Contribution
0.468
From 30 citing papers with measurable signal
Top 5 citers driving the network score
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 45 citers.
- CD47 as a potential predictive biomarker in colorectal cancerJournal for ImmunoTherapy of Cancer20253 citations19 referencesContributes 0.073
- Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitorsInternational Immunopharmacology202411 citations61 referencesContributes 0.041
- Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancerThe Journal of Experimental Medicine202424 citations87 referencesContributes 0.037
- Metformin in Colorectal Cancer: Epidemiological Evidence, Predictive Biomarkers, and Implications for Prevention and TreatmentInternational Journal of Molecular Sciences20259 citations70 referencesContributes 0.033
- Mitochondrial transfer at the crossroads of cancer, stromal, and immune cellsTrends in Cell Biology20258 citations70 referencesContributes 0.031
Authors (14)
Bristol-Myers Squibb
Grant: N/A
Winship Cancer Institute of Emory University
Grant: P30CA138292
NCI NIH HHS
Grant: P30 CA013148
National Institutes of Health
Grant: 5P30CA138292-11
Winship Cancer Institute Cancer Center Support Grant
Fields of Study
MeSH Terms
Keywords